Navigation Links
NovaBay Pharmaceuticals' Scientific Advisor Receives American Chemical Society's Highest Award
Date:3/23/2009

M. Frederick Hawthorne, Ph.D. Honored for Distinguished Service in the Field of Chemistry

EMERYVILLE, Calif., March 23 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Alternext: NBY) today announced that world-renowned scientist M. Frederick Hawthorne, Ph.D., a member of the Company's Scientific Advisory Board will be the recipient of the 2009 Priestley Medal, the highest honor awarded by the American Chemical Society (ACS). Dr. Hawthorne, who is co-director of the International Institute for Nano and Molecular Medicine at the University of Missouri-Columbia, will be presented this award for distinguished service in the field of chemistry at the Spring ACS National Meeting to be held this week in Salt Lake City, Utah.

"Dr. Hawthorne is a world-renowned scientist who has brought his impeccable credentials and expertise to NovaBay," said Dr. Ron Najafi, chairman and chief executive officer of NovaBay. "We are extremely proud and honored to have such a distinguished leader of the chemical community on our Scientific Advisory Board. We congratulate him on receiving the prestigious 2009 Priestley Medal."

Dr. Hawthorne has contributed to the development of NovaBay's Aganocide(R) class of antimicrobial molecules specifically designed by NovaBay to mimic the body's natural defense against infection. These compounds may deliver the same or better level of antimicrobial activity as is currently reached by common antibiotics without contributing to the growing rise in bacterial resistance. The Aganocide compounds have shown in preclinical trials to date to be highly effective against bacteria, viruses and fungi. They have also been demonstrated to be effective against bacteria in biofilm, for which most antibiotics are rendered ineffective. These compounds have a potentially broad therapeutic index providing a high degree of potency, good tolerability, together with dosing versatility and flexibility.

Dr. Hawthorne began his 60-year career in chemistry working with the element, boron. He created a wide variety of novel polyboranes and carboranes and discovered uses for these compounds for applications in medical imaging, drug delivery, neutron-based treatments for cancers and rheumatoid arthritis, catalysis and molecular motors. He also created a specific type of nanoparticle that selectively targets cancer cells for boron neutron capture therapy. Dr. Hawthorne was elected to the National Academy of Sciences in 1973 at the age of 44. Professor Hawthorne is the recipient of many awards and honors over his distinguished career. He has authored or co-authored more than 500 research articles, 30 patents and 10 book chapters. He has mentored and directed the research of nearly 200 Ph.D. students and postdoctoral associates from 21 countries. Thirty-five (35) now hold academic positions. Many have risen to high positions in industry and one was a space shuttle astronaut.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a mid-stage biopharmaceutical company developing first-in-class, novel, synthetic anti-infective product candidates. These products are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without developing resistance. NovaBay has entered into a licensing and research collaboration agreement with Alcon, Inc. for use of the Aganocide compounds in the eye, ear and sinus, and in contact lens solutions. NovaBay(R) and Aganocide(R) are trademarks of NovaBay Pharmaceuticals, Inc. For more information on NovaBay, visit www.novabaypharma.com.

Cautionary Information Regarding Forward-Looking Statements

Statements in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, the risk that results obtained in pre-clinical studies may not be obtained in humans, and the risk of unexpected delays in the regulatory process may delay the commencement or completion of clinical trials. Other risks relating to NovaBay's Aganocide compounds, including risks that could cause actual results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Quarterly Report on Form 10-Q/A for the period ended September 30, 2008, under the caption "Risk Factors" in Item 1A of Part II of that report, which was filed with the Securities and Exchange Commission on November 14, 2008.


'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
2. NovaBay announces third quarter 2007 financial results
3. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... -- Guerbet announced today that it has been named a ... One of 12 suppliers to receive the ... of Premier members through exceptional local customer service and ... lower costs. "We ... customer service from Premier," says Massimo Carrara , ...
Breaking Medicine Technology: